Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Vaxzevria prime and Comirnaty boost vaccination
2021-002171-19Phase 2Completed
- Sponsor
- Institute of Virology, Medical University of Innsbruck
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of tozinameran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Institute of Virology, Medical University of Innsbruck. Primary endpoints: Neutralizing antibody levels and Clinical efficacy against infection by variants. Started Apr 2021; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002171-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002171-19.